Supporting Information

Highly Penetrative Liposome Nanomedicine Generated by Biomimetic Strategy for Enhanced Cancer Chemotherapy

Yali Jia,[#a.b] Zonghai Sheng,[#a.b] Dehong Hu,[b] Fei Yan,[b] Mingting Zhu,[a.b] Guanhui Gao,[c] Pan Wang,[a] Xin Liu,[b] Xiaobing Wang*[a.b] and Hairong Zheng*[a]



Fig. S1 Z-average diameter changes of the liposomes detected by DLS measurement after 15 days of storage in PBS buffer.



Fig. S2 Diameter changes of M-Lipo-DOX after storage in FBS containing different

concentrations of FBS.



Fig. S3 Analysis of *in vitro* release profile of DOX using the dialysis method.



Fig. S4 DOX fluorescence intensity of different cells after incubation with M-Lipo-DOX.



Fig. S5 Fluorescence images of C6-GFP treated with DOX, Lipo-DOX, and M-Lipo-DOX for 24 h. The bar indicates 20 μm.



Fig. S6 Multi-level scan of the penetration of Lipo-DOX and M-Lipo-DOX, respectively, the interval between the consecutive slides was 10 μm. The bar indicates 100 μm.



Fig. S7 Blood circulation time of DOX after intravenous administration with DOX, Lipo-DOX, and M-Lipo-DOX, respectively.



Fig. S8 Tumor weight in different groups on the 18th day after treatment. *p< 0.05, **p< 0.01 versus the control.



Fig. S9 Body weight curve of C6 tumor-bearing nude mice during treatment.